1. Circ Heart Fail. 2020 Oct;13(10):e006832. doi: 
10.1161/CIRCHEARTFAILURE.119.006832. Epub 2020 Sep 23.

Clinical Phenotypes and Prognosis of Dilated Cardiomyopathy Caused by Truncating 
Variants in the TTN Gene.

Akhtar MM(1)(2), Lorenzini M(1)(2), Cicerchia M(3)(4), Ochoa JP(3)(4), Hey 
TM(5)(6), Sabater Molina M(7), Restrepo-Cordoba MA(8)(9), Dal Ferro M(10), 
Stolfo D(10), Johnson R(11), Larrañaga-Moreira JM(12), Robles-Mezcua A(13), 
Rodriguez-Palomares JF(14), Casas G(14), Peña-Peña ML(15), Lopes LR(1)(2), 
Gallego-Delgado M(16), Franaszczyk M(17), Laucey G(18), Rangel-Sousa D(15), 
Basurte M(18), Palomino-Doza J(19)(20), Villacorta E(16), Bilinska Z(21), 
Limeres Freire J(14), Garcia Pinilla JM(13), Barriales-Villa R(12), Fatkin 
D(22)(23)(24), Sinagra G(10), Garcia-Pavia P(8)(9), Gimeno JR(7), Mogensen 
J(5)(6), Monserrat L(3)(4), Elliott PM(1)(2).

Author information:
(1)Department of Inherited Cardiovascular Diseases, Bart's Heart Centre, St. 
Bartholomew's Hospital, London, United Kingdom (M.M.A., M.L., L.R.L., P.M.E.).
(2)Institute of Cardiovascular Science, University College London, United 
Kingdom (M.M.A., M.L., L.R.L., P.M.E.).
(3)Health in Code S.L. Scientific Department, A Coruña, Spain (M.C., J.P.O., 
L.M.).
(4)Instituto de Investigación Biomédica de A Coruña, Complexo Hospitalario 
Universitario de A Coruña, Sergas, Universidade da Coruña, Spain (M.C., J.P.O., 
L.M.).
(5)Department of Cardiology, Odense University Hospital, Denmark (T.M.H., J.M.).
(6)Odense Patient Data Explorative Network, University of Southern Denmark 
(T.M.H., J.M.).
(7)Inherited Cardiac Disease Unit, Hospital Universitario Virgen Arrixaca, 
Murcia, Spain (M.S.M., J.R.G.).
(8)Heart Failure and Inherited Cardiac Diseases Unit, Department of Cardiology, 
Hospital Universitario Puerta de Hierro, Centro de Investigación en Red en 
Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain (M.A.R.-C., P.G.-P.).
(9)Universidad Francisco de Vitoria, Pozuelo de Alarcon, Spain (M.A.R.-C., 
P.G.-P.).
(10)Cardiovascular Department, Azienda Sanitaria Universitaria Integrata of 
Trieste, Trieste Hospital, Italy (M.D.F., D.S., G.S.).
(11)Molecular Cardiology and Biophysics Division (R.J.), Victor Chang Cardiac 
Research Institute, Darlinghurst, NSW, Australia.
(12)Unidad de Cardiopatías Familiares/Cardiology Service, CIBERCV, Instituto de 
Investigación Biomédica de A Coruña, Complexo Hospitalario Universitario de A 
Coruña, Sergas, Universidade da Coruña, Spain (J.M.L.-M., R.B.-V.).
(13)Heart Failure and Familial Heart Diseases Unit, Cardiology Department, 
Hospital Universitario Virgen de la Victoria, CIBERCV, IBIMA, Malaga, Spain 
(A.R.-M., J.M.G.P.).
(14)Department of Cardiology, Vall d' Hebron Institut de Recerca, Hospital 
Universitari Vall d' Hebron, Universitat Autònoma de Barcelona, Spain 
(J.F.R.-P., G.C., J.L.F.).
(15)Heart Failure and Heart Transplantation Unit, Virgen del Rocio University 
Hospital, Sevilla, Spain (M.L.P.-P., D.R.-S.).
(16)Inherited Cardiovascular Disease Unit, Cardiology Department, Instituto de 
Investigación Biomédica de Salamanca, Complejo Asistencial Universitario de 
Salamanca, Spain (M.G.-D., E.V.).
(17)Department of Medical Biology (M.F.), Cardinal Stefan Wyszynski Institute of 
Cardiology, Warsaw, Poland.
(18)Complejo Hospitalario de Navarra, Pamplona, Spain (G.L., M.B.).
(19)Inherited Cardiac Disease Unit, Instituto de investigación I+12, Hospital 
Universitario 12 de Octubre, Madrid, Spain (J.P.-D.).
(20)Centro de Investigación Biomedica en Red en Enfermedades Cardiovasculares, 
CIBERCV, Madrid, Spain (J.P.-D.).
(21)Unit for Screening Studies in Inherited Cardiovascular Diseases (Z.B.), 
Cardinal Stefan Wyszynski Institute of Cardiology, Warsaw, Poland.
(22)Molecular Cardiology and Biophysics Division (D.F.), Victor Chang Cardiac 
Research Institute, Darlinghurst, NSW, Australia.
(23)St. Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Kensington, 
NSW, Australia (D.F.).
(24)Cardiology Department, St. Vincent's Hospital, Darlinghurst, NSW, Australia 
(D.F.).

BACKGROUND: Truncating variants in the TTN gene (TTNtv) are the commonest cause 
of heritable dilated cardiomyopathy. This study aimed to study the phenotypes 
and outcomes of TTNtv carriers.
METHODS: Five hundred thirty-seven individuals (61% men; 317 probands) with 
TTNtv were recruited in 14 centers (372 [69%] with baseline left ventricular 
systolic dysfunction [LVSD]). Baseline and longitudinal clinical data were 
obtained. The primary end point was a composite of malignant ventricular 
arrhythmia and end-stage heart failure. The secondary end point was left 
ventricular reverse remodeling (left ventricular ejection fraction increase by 
≥10% or normalization to ≥50%).
RESULTS: Median follow-up was 49 (18-105) months. Men developed LVSD more 
frequently and earlier than women (45±14 versus 49±16 years, respectively; 
P=0.04). By final evaluation, 31%, 45%, and 56% had atrial fibrillation, 
frequent ventricular ectopy, and nonsustained ventricular tachycardia, 
respectively. Seventy-six (14.2%) individuals reached the primary end point (52 
[68%] end-stage heart failure events, 24 [32%] malignant ventricular arrhythmia 
events). Malignant ventricular arrhythmia end points most commonly occurred in 
patients with severe LVSD. Male sex (hazard ratio, 1.89 [95% CI, 1.04-3.44]; 
P=0.04) and left ventricular ejection fraction (per 10% decrement from left 
ventricular ejection fraction, 50%; hazard ratio, 1.63 [95% CI, 1.30-2.04]; 
P<0.001) were independent predictors of the primary end point. Two hundred seven 
of 300 (69%) patients with LVSD had evidence of left ventricular reverse 
remodeling. In a subgroup of 29 of 74 (39%) patients with initial left 
ventricular reverse remodeling, there was a subsequent left ventricular ejection 
fraction decrement. TTNtv location was not associated with statistically 
significant differences in baseline clinical characteristics, left ventricular 
reverse remodeling, or outcomes on multivariable analysis (P=0.07).
CONCLUSIONS: TTNtv is characterized by frequent arrhythmia, but malignant 
ventricular arrhythmias are most commonly associated with severe LVSD. Male sex 
and LVSD are independent predictors of outcomes. Mutation location does not 
impact clinical phenotype or outcomes.

DOI: 10.1161/CIRCHEARTFAILURE.119.006832
PMID: 32964742 [Indexed for MEDLINE]